Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 2Tobacco Use Disorder 1Smoking Cessation 1Skin Neoplasms 1Noncommunicable Diseases 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Lymphatic Abnormalities 1Lymphangioma 1Lung Neoplasms 1Ischemic Stroke 1Chronic Disease 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Behavior 1Abdomen, Acute 1

Interventions

Cetuximab 6Cisplatin 4pembrolizumab 3Fluorouracil 3zalutumumab 2Paclitaxel 2Nivolumab 2Gefitinib 2temsirolimus 1sintilimab 1osimertinib 1cobimetinib 1Vorinostat 1Sorafenib 1Risk Factors 1Ribavirin 1Radiotherapy 1Proflavine 1Pemetrexed 1Jogging 1Imatinib Mesylate 1Docetaxel 1Dexamethasone 1Cyclophosphamide 1Cilengitide 1Carboplatin 1Calcium Dobesilate 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms, Squamous Cell × Risk Factors × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡